Browse LRRC16A

Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasm, cytoskeleton Cell membrane Cell projection, lamellipodium Note=Colocalized with heterodimeric capping protein (CP) and F-actin in lamellipodia but not with F-actin in stress fibers (PubMed:19846667). Colocalized with F-actin in lamellipodia but not with F-actin in stress fibers (PubMed:19846667). Found on macropinosomes (PubMed:19846667).
Domain PF16000 CARMIL C-terminus
PF13516 Leucine Rich repeat
Function

Cell membrane-cytoskeleton-associated protein that plays a role in the regulation of actin polymerization at the barbed end of actin filaments. Prevents F-actin heterodimeric capping protein (CP) activity at the leading edges of migrating cells, and hence generates uncapped barbed ends and enhances actin polymerization, however, seems unable to nucleate filaments (PubMed:16054028). Plays a role in lamellipodial protrusion formations and cell migration (PubMed:19846667).

> Gene Ontology
 
Biological Process GO:0006907 pinocytosis
GO:0007015 actin filament organization
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010639 negative regulation of organelle organization
GO:0010720 positive regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0022604 regulation of cell morphogenesis
GO:0030031 cell projection assembly
GO:0030032 lamellipodium assembly
GO:0030038 contractile actin filament bundle assembly
GO:0030041 actin filament polymerization
GO:0030042 actin filament depolymerization
GO:0030335 positive regulation of cell migration
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030834 regulation of actin filament depolymerization
GO:0030835 negative regulation of actin filament depolymerization
GO:0030836 positive regulation of actin filament depolymerization
GO:0030837 negative regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031032 actomyosin structure organization
GO:0031333 negative regulation of protein complex assembly
GO:0031334 positive regulation of protein complex assembly
GO:0031346 positive regulation of cell projection organization
GO:0031529 ruffle organization
GO:0031589 cell-substrate adhesion
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032271 regulation of protein polymerization
GO:0032272 negative regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0032984 macromolecular complex disassembly
GO:0034446 substrate adhesion-dependent cell spreading
GO:0040017 positive regulation of locomotion
GO:0043149 stress fiber assembly
GO:0043241 protein complex disassembly
GO:0043242 negative regulation of protein complex disassembly
GO:0043243 positive regulation of protein complex disassembly
GO:0043244 regulation of protein complex disassembly
GO:0043254 regulation of protein complex assembly
GO:0043624 cellular protein complex disassembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0044351 macropinocytosis
GO:0045785 positive regulation of cell adhesion
GO:0046415 urate metabolic process
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051016 barbed-end actin filament capping
GO:0051017 actin filament bundle assembly
GO:0051258 protein polymerization
GO:0051261 protein depolymerization
GO:0051272 positive regulation of cellular component movement
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0051638 barbed-end actin filament uncapping
GO:0051639 actin filament network formation
GO:0051693 actin filament capping
GO:0051695 actin filament uncapping
GO:0061572 actin filament bundle organization
GO:0090066 regulation of anatomical structure size
GO:0097581 lamellipodium organization
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading
GO:1901879 regulation of protein depolymerization
GO:1901880 negative regulation of protein depolymerization
GO:1901881 positive regulation of protein depolymerization
GO:1902743 regulation of lamellipodium organization
GO:1902745 positive regulation of lamellipodium organization
GO:2000147 positive regulation of cell motility
GO:2000812 regulation of barbed-end actin filament capping
GO:2000813 negative regulation of barbed-end actin filament capping
Molecular Function -
Cellular Component GO:0005884 actin filament
GO:0015629 actin cytoskeleton
GO:0030027 lamellipodium
GO:0031252 cell leading edge
GO:0031941 filamentous actin
GO:0044352 pinosome
GO:0044354 macropinosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-109582: Hemostasis
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRRC16A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRRC16A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRRC16A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8570.0242
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.6140.158
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3040.736
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2710.339
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3250.881
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1980.94
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5050.245
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.230.366
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2960.846
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1130.917
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2640.86
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0760.434
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LRRC16A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRRC16A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRRC16A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRRC16A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRRC16A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRRC16A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRRC16A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRRC16A
Nameleucine rich repeat containing 16A
Aliases dJ501N12.1; FLJ20048; CARMIL; CARMIL1; capping protein, Arp2/3, and Myosin-I Linker homolog 1 (Dictyostelium ......
Chromosomal Location6p22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRRC16A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.